LOCOREGIONALLY ADVANCED NASOPHARYNGEAL CARCINOMA
Clinical trials for LOCOREGIONALLY ADVANCED NASOPHARYNGEAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LOCOREGIONALLY ADVANCED NASOPHARYNGEAL CARCINOMA trials appear
Sign up with your email to follow new studies for LOCOREGIONALLY ADVANCED NASOPHARYNGEAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to shrink throat tumors before standard care
Disease control Not yet recruitingThis phase 2 trial tests whether giving pembrolizumab (an immunotherapy) plus MRG-003 (a targeted drug) before standard chemoradiation can improve outcomes for people with advanced, EBV-related nasopharyngeal cancer. About 35 participants will receive the combination for 3 cycles…
Matched conditions: LOCOREGIONALLY ADVANCED NASOPHARYNGEAL CARCINOMA
Phase: PHASE2 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 16, 2026 02:33 UTC
-
New drug aims to stop throat cancer from coming back
Disease control Not yet recruitingThis study tests a new drug, Becotatug vedotin, against a standard chemotherapy pill (capecitabine) to see which is better at preventing cancer from returning in people with advanced nasopharyngeal cancer. About 218 adults who have already completed standard chemoradiation will b…
Matched conditions: LOCOREGIONALLY ADVANCED NASOPHARYNGEAL CARCINOMA
Phase: PHASE2 • Sponsor: Kai Hu • Aim: Disease control
Last updated May 11, 2026 20:41 UTC